Pomalidomide-PEG4-C2-NH2 hydrochloride

Background Introduction

Pomalidomide-PEG4-C2-NH2 hydrochloride is a specialized E3 ligase ligand-linker conjugate designed for targeted protein degradation applications. This compound integrates pomalidomide, a well-established ligand for the cereblon (CRBN) E3 ubiquitin ligase, with a hexadecaethylene glycol-based PEG4 spacer and an amine-terminated linker, enabling versatile attachment to various molecular warheads or cargos used in PROTAC (Proteolysis Targeting Chimera) design.

Mechanism

The mechanism of action of Pomalidomide-PEG4-C2-NH2 hydrochloride centers on its ability to recruit the CRBN E3 ubiquitin ligase when incorporated into bifunctional PROTACs. The pomalidomide moiety selectively binds to CRBN, facilitating the proximity-induced ubiquitination of the protein of interest (POI) that is tethered via the linker. The attached linker (PEG4-C2-NH2) offers optimal flexibility and solubility, reducing steric hindrance and improving the pharmacokinetic properties of the resulting conjugate. This design enables efficient polyubiquitination and subsequent proteasomal degradation of the POI, allowing for selective post-translational protein knockdown.

Applications

Pomalidomide-PEG4-C2-NH2 hydrochloride is widely used in chemical biology and drug discovery for the development of novel PROTACs and molecular glues targeting the CRBN E3 ligase. Its application includes building custom PROTAC molecules for targeted degradation of disease-relevant proteins, enabling research in oncology, neurodegenerative disorders, and immunology. Researchers also employ this conjugate in screening platforms for validating E3 ligase engagement and optimizing linker lengths for structure-activity relationship (SAR) studies. The hydrochloride salt form enhances its stability and ease of use in medicinal chemistry workflows, supporting both in vitro and in vivo studies.

• PEG4-based flexible linker improves solubility and pharmacokinetic properties of resulting PROTACs.
• Tailored for efficient CRBN E3 ligase recruitment, enabling potent targeted protein degradation applications.

Pomalidomide-PEG4-C2-NH2 hydrochloride serves as a versatile E3 Ligase Ligand-Linker Conjugate in PROTACs, facilitating targeted protein degradation by bridging E3 ligase and target proteins. The following provides a detailed description of this molecule, focusing on its linker, ligand, and selection of target protein ligands.

Linker: The linker in this molecule is a PEG4 chain, offering moderate length and flexibility, which enhances solubility and bioavailability. Its non-cleavable nature ensures stability during the degradation process, making it suitable for robust experimental applications.

Ligand: The ligand component is based on pomalidomide, a thalidomide derivative, known for its high affinity to cereblon, an E3 ligase. Its structural characteristics allow for efficient recruitment of the E3 ligase complex, facilitating the ubiquitination and subsequent degradation of target proteins.

Reactive Site: The reactive site is an amine group (NH2) at the terminus of the linker, which couples with the target protein ligand through amide bond formation. This site is optimal for nucleophilic acyl substitution reactions, providing a stable conjugation point for target engagement.

Recommended Target Protein Ligand: The recommended warhead for this molecule is a small-molecule inhibitor or binding motif with a reactive carboxylic acid group. This configuration allows for efficient coupling through amide bond formation, promoting specificity and potency in protein degradation applications. Such warheads are advantageous for their ability to precisely modulate protein levels, offering a powerful tool for mechanistic studies and drug discovery research.